Author:
Rhodin Kristen E.,Lidsky Michael E.
Publisher
Springer Science and Business Media LLC
Reference5 articles.
1. Chan E, Berlin J. Biliary tract cancers: understudied and poorly understood. J Clin Oncol. 2015;33(16):1845–8. https://doi.org/10.1200/jco.2014.59.7591.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: hepatobiliary cancers. Updated July 15, 2022. Accessed September 10, 2022. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.
3. Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–73. https://doi.org/10.1016/s1470-2045(18)30915-x.
4. Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12):1015–27. https://doi.org/10.1200/jco.18.02178.
5. Rhodin KE, Liu A, Bartholomew A, et al. Trends in receipt of adjuvant chemotherapy and impact on survival in resected biliary tract cancer. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-13567-4.